499 related articles for article (PubMed ID: 24488705)
1. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
Osman MM; Chaar BT; Muzaffar R; Oliver D; Reimers HJ; Walz B; Nguyen NC
AJR Am J Roentgenol; 2010 Dec; 195(6):1397-403. PubMed ID: 21098201
[TBL] [Abstract][Full Text] [Related]
3. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
[TBL] [Abstract][Full Text] [Related]
4. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
Niederkohr RD; Rosenberg J; Shabo G; Quon A
Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
[TBL] [Abstract][Full Text] [Related]
6. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
7. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
8. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
Tatsumi M; Miller JH; Wahl RL
J Nucl Med; 2007 Dec; 48(12):1923-31. PubMed ID: 18056332
[TBL] [Abstract][Full Text] [Related]
10. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
11. Missed causative tumors in diagnosing tumor-induced osteomalacia with (18)F-FDG PET/CT: a potential pitfall of standard-field imaging.
Kaneuchi Y; Hakozaki M; Yamada H; Hasegawa O; Tajino T; Konno S
Hell J Nucl Med; 2016; 19(1):46-8. PubMed ID: 26929940
[TBL] [Abstract][Full Text] [Related]
12. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS
Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667
[TBL] [Abstract][Full Text] [Related]
13. Dual-time-point (18)F-FDG-PET/CT imaging in the assessment of suspected malignancy.
Chan WL; Ramsay SC; Szeto ER; Freund J; Pohlen JM; Tarlinton LC; Young A; Hickey A; Dura R
J Med Imaging Radiat Oncol; 2011 Aug; 55(4):379-90. PubMed ID: 21843173
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
15. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
Lazaga FJ; Oz OK; Adams-Huet B; Anderson J; Mathews D
Clin Nucl Med; 2013 Nov; 38(11):882-4. PubMed ID: 24096999
[TBL] [Abstract][Full Text] [Related]
16. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
18. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
[TBL] [Abstract][Full Text] [Related]
19. Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma.
Wang LJ; Wu HB; Wang M; Han YJ; Li HS; Zhou WL; Wang QS
Eur J Radiol; 2015 Nov; 84(11):2275-9. PubMed ID: 26388466
[TBL] [Abstract][Full Text] [Related]
20. The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging.
Hausmann D; Dinter DJ; Sadick M; Brade J; Schoenberg SO; Büsing K
J Nucl Med Technol; 2012 Dec; 40(4):255-8. PubMed ID: 23071347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]